These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Why do we need new and better antidepressants? Montgomery SA Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S1-S10. PubMed ID: 16436933 [TBL] [Abstract][Full Text] [Related]
43. Treatment and outcome of antidepressant treatment-associated hypomania in unipolar major depression: a 3-year follow-up study. Navarro V; Gastó C; Guarch J; Penadés R; Pintor L J Affect Disord; 2014 Feb; 155():59-64. PubMed ID: 24252168 [TBL] [Abstract][Full Text] [Related]
44. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. Pardini M; Cordano C; Benassi F; Mattei C; Sassos D; Guida S; Serrati C; Primavera A; Amore M; Cocito L; Emberti Gialloreti L Eur Neuropsychopharmacol; 2014 Jun; 24(6):939-44. PubMed ID: 24636462 [TBL] [Abstract][Full Text] [Related]
45. Antidepressant-associated mania or hypomania: a comparison with personality and bipolarity features of bipolar I disorder. Saatcioglu O; Erim R; Tomruk N; Oral T; Alpay N J Affect Disord; 2011 Nov; 134(1-3):85-90. PubMed ID: 21632117 [TBL] [Abstract][Full Text] [Related]
46. The preclinical discovery and development of agomelatine for the treatment of depression. Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567 [TBL] [Abstract][Full Text] [Related]
51. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372 [TBL] [Abstract][Full Text] [Related]
53. Sleep disturbances and depression: a challenge for antidepressants. Lam RW Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S25-9. PubMed ID: 16436937 [TBL] [Abstract][Full Text] [Related]
54. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703 [TBL] [Abstract][Full Text] [Related]
55. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Ghosh A; Hellewell JS Expert Opin Investig Drugs; 2007 Dec; 16(12):1999-2004. PubMed ID: 18042007 [TBL] [Abstract][Full Text] [Related]
56. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. San L; Arranz B Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104 [TBL] [Abstract][Full Text] [Related]
57. Agomelatine for the treatment of posttraumatic stress disorder: a case report. De Berardis D; Serroni N; Marini S; Moschetta FS; Martinotti G; Di Giannantonio M Ann Clin Psychiatry; 2012 Aug; 24(3):241-2. PubMed ID: 22860244 [No Abstract] [Full Text] [Related]
58. [Agomelatine: the first "melatoninergic" antidepressant]. Bánki MC Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046 [TBL] [Abstract][Full Text] [Related]
59. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Bertaina-Anglade V; la Rochelle CD; Boyer PA; Mocaër E Behav Pharmacol; 2006 Dec; 17(8):703-13. PubMed ID: 17110796 [TBL] [Abstract][Full Text] [Related]
60. Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice. Laux G; Barthel B; Hajak G; Lemke M; Volz HP Adv Ther; 2017 Apr; 34(4):895-914. PubMed ID: 28214983 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]